NASDAQ: SPRO

Spero Therapeutics, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Spero Therapeutics, Inc. (NASDAQ: SPRO) between May 6, 2021 and May 2, 2022, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than July 25, 2022.

If you purchased Spero Therapeutics securities during the Class Period and would like to join the action, please click “Join This Class Action.”

Class Period:May 6, 2021 through May 2, 2022

If you purchased Spero Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of the case:

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:

the data submitted in support of the New Drug Application (“NDA”) of Tebipenem HBr, an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults, were insufficient to obtain U.S. Food and Drug Administration (“FDA”) approval;
accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form;
the foregoing would necessitate a significant workforce reduction and restructuring of Spero Therapeutics’s operations; and
as a result, the Company’s public statements were materially false and misleading at all relevant times.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.